Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05377996 · ClinicalTrials.gov registry record · Phase 1

A Study of XMT-1660 in Participants With Solid Tumors

A Phase 1 study of Breast Cancer and Ovarian Cancer, sponsored by Mersana Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
319
Enrollment target
20
Study locations

NCT05377996 is a Phase 1 study of Breast Cancer and Ovarian Cancer that is actively recruiting participants, run by Mersana Therapeutics. The registered enrollment target is 319 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05377996, a Phase 1 study of Breast Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Mersana Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
319 participants
Enrollment target
20
Study locations

Study Summary

A Study of XMT-1660 in Solid Tumors

Conditions Studied

Breast Cancer Ovarian Cancer Endometrial Cancer Triple Negative Breast Cancer Fallopian Tube Cancer Primary Peritoneal Cavity Cancer Adenoid Cystic Carcinoma

Interventions

  • DRUG XMT-1660

Study Locations (20)

California

  • UC Irvine Health-Chao Family Comprehensive Cancer Center - Orange
  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
  • UCLA - Santa Monica

Florida

  • Mayo Clinic - Jacksonville - Jacksonville
  • Florida Cancer Specialists - Sarasota
  • Moffitt Cancer Center - Tampa

New York

  • New York University Langone Health - New York
  • ICHAN School of Medicine at Mount Sinai - New York
  • Memorial Sloan Kettering Cancer Center - New York

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

Arizona

  • Mayo Clinic Comprehensive Cancer Center - Phoenix

Georgia

  • Winship Cancer Institute, Emory University - Atlanta

Illinois

  • Northwestern University - Chicago

Michigan

  • Henry Ford Health Hospital - Detroit

Trial Details

FieldValue
Enrollment Target 319 participants
Start Date 2022-08-15
Est. Completion 2027-05
Phase Phase 1

Sponsor

Mersana Therapeutics

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05377996

The ClinicalTrials.gov registry entry for NCT05377996 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 319 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Mersana Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which XMT-1660 is the first listed.

NCT05377996 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT05377996 about?

NCT05377996 is a clinical study titled "A Study of XMT-1660 in Participants With Solid Tumors". A Study of XMT-1660 in Solid Tumors

What is the current status of trial NCT05377996?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 319 participants. The study started on 2022-08-15. Estimated completion is 2027-05.

What conditions does trial NCT05377996 study?

This clinical trial studies the following conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Fallopian Tube Cancer.

What interventions are being tested in trial NCT05377996?

The interventions under investigation include: XMT-1660 (DRUG).

Who is sponsoring clinical trial NCT05377996?

This trial is sponsored by Mersana Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05377996 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Ovarian Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.